Antibody variant combinations and uses thereof
Provided herein are combinations of first and second antibodies having modified Fc effector functions resulting from amino acid substitutions in the Fc region, the amino acid substitutions allow for co-dependent activation of effector functions such as CDC and/or ADCC. Also provided are combinations of first and second antibodies having agonistic activity or enhanced agonistic activity resulting from amino acid substitutions in the Fc region where the agonistic activity is co-dependent of both a first and second antibodies.
1. A method for treating a disease or disorder, the method comprising administering to a subject in need thereof a first antibody comprising a first Fc region of a human IgG and a first antigen-binding region capable of binding to a first antigen, and a second antibody comprising a second Fc region of a human IgG and a second antigen-binding region capable of binding to a second antigen, wherein the first Fc region comprises G236R, E345R, and K439E substitutions and the second Fc region comprises G237A, E345R, and S440K substitutions, and
wherein the amino acid positions correspond to human IgG1 according to Eu numbering system.
2. The method of claim 1 , wherein the first and/or second antibody is human, humanized, or chimeric.
3. The method of claim 1 , wherein the first and/or second antibody is a monoclonal antibody.
4. The method of claim 1 , wherein the first and/or second antibody is a human IgG1, IgG2, IgG3 or IgG4 isotype.
5. The method of claim 1 , wherein the first and second antigens are (a) both cell surface-exposed molecules and/or (b) co-located in cells or tissues that are target cells or target tissue for the disease or disorder to be treated.
6. The method of claim 1 , wherein the first and second antigens are not identical.
7. The method of claim 1 , which results in the depletion of a cell population expressing the first and second antigen.
8. The method of claim 7 , wherein the cell population is a tumor cell.
9. The method of claim 8 , wherein the cell population is a hematological tumor cell or a solid tumor cell.
10. The method of claim 7 , wherein the cell population is a leukocyte, lymphocyte, B cell, T cell, regulatory T cell, NK cell, myeloid derived suppressor cell, or tumor associated macrophage cell population.
11. A composition comprising a first and a second antibody, wherein the first antibody comprises a first antigen-binding region capable of binding to a first antigen and a first Fc region of a human IgG, and the second antibody comprises a second antigen-binding region capable of binding to a second antigen and a second Fc region of a human IgG, wherein the first Fc region comprises G236R, E345R, and K439E substitutions and the second Fc region comprises G237A, E345R, and S440K substitutions, and
wherein the amino acid positions correspond to human IgG1 according to Eu numbering system.
12. The method of claim 1 , wherein the antigen-binding region is capable of binding to an antigen selected from the group consisting of: DR4, DR5, CD20, CD37, CD52, HLA-DR, CD3, CD5, 4-1BB, and PD1.
13. The method of claim 1 , wherein the antigen-binding region of the first antibody and second antibody comprises a VH region and VL region selected from the group consisting of:
(a) a VH region comprising a CDR1 sequence as set forth in SEQ ID NO:196, a CDR2 sequence as set forth in SEQ ID NO:196 and a CDR3 sequence as set forth SEQ ID NO:198, and a VL region comprising a CDR1 sequence as set forth in SEQ ID NO:200, a CDR2 sequence as set forth in: AAT and a CDR3 sequence as set forth SEQ ID NO:201;
(b) a VH region comprising a CDR1 sequence as set forth in SEQ ID NO:50, a CDR2 sequence as set forth in SEQ ID NO:51 and a CDR3 sequence as set forth SEQ ID NO:52, and a VL region comprising a CDR1 sequence as set forth in SEQ ID NO:54, a CDR2 sequence as set forth in: FAS and a CDR3 sequence as set forth SEQ ID NO:55;
(c) a VH region comprising a CDR1 sequence as set forth in SEQ ID NO:57, a CDR2 sequence as set forth in SEQ ID NO:58 and a CDR3 sequence as set forth SEQ ID NO:59, and a VL region comprising a CDR1 sequence as set forth in SEQ ID NO:61, a CDR2 sequence as set forth in: RTS and a CDR3 sequence as set forth SEQ ID NO:62;
(d) a VH region comprising a CDR1 sequence as set forth in SEQ ID NO:36, a CDR2 sequence as set forth in SEQ ID NO:37 and a CDR3 sequence as set forth SEQ ID NO:38, and a VL region comprising a CDR1 sequence as set forth in SEQ ID NO:40, a CDR2 sequence as set forth in: DAS and a CDR3 sequence as set forth SEQ ID NO:41;
(e) a VH region comprising a CDR1 sequence as set forth in SEQ ID NO:9, a CDR2 sequence as set forth in SEQ ID NO:10 and a CDR3 sequence as set forth SEQ ID NO:11, and a VL region comprising a CDR1 sequence as set forth in SEQ ID NO: 13, a CDR2 sequence as set forth in: DAS and a CDR3 sequence as set forth SEQ ID NO:14;
(f) a VH region comprising a CDR1 sequence as set forth in SEQ ID NO:43, a CDR2 sequence as set forth in SEQ ID NO:44 and a CDR3 sequence as set forth SEQ ID NO:45, and a VL region comprising a CDR1 sequence as set forth in SEQ ID NO:47, a CDR2 sequence as set forth in: VAT and a CDR3 sequence as set forth SEQ ID NO:48;
(g) a VH region comprising a CDR1 sequence as set forth in SEQ ID NO:2, a CDR2 sequence as set forth in SEQ ID NO:3 and a CDR3 sequence as set forth SEQ ID NO:4, and a VL region comprising a CDR1 sequence as set forth in SEQ ID NO:6, a CDR2 sequence as set forth in: NTN, and a CDR3 sequence as set forth SEQ ID NO:7;
(h) a VH region comprising a CDR1 sequence as set forth in SEQ ID NO:161, a CDR2 sequence as set forth in SEQ ID NO:162, and a CDR3 sequence as set forth SEQ ID NO:163, and a VL region comprising a CDR1 sequence as set forth in SEQ ID NO: 165, a CDR2 sequence as set forth in: LVS and a CDR3 sequence as set forth SEQ ID NO:166;
(i) Q a VH region comprising a CDR1 sequence as set forth in SEQ ID NO:168, a CDR2 sequence as set forth in SEQ ID NO:169 and a CDR3 sequence as set forth SEQ ID NO:170, and a VL region comprising a CDR1 sequence as set forth in SEQ ID NO: 172, a CDR2 sequence as set forth in SEQ ID NO:AAS and a CDR3 sequence as set forth SEQ ID NO:173;
(j) a VH region comprising a CDR1 sequence as set forth in SEQ ID NO:175, a CDR2 sequence as set forth in SEQ ID NO:176 and a CDR3 sequence as set forth SEQ ID NO:177, and a VL region comprising a CDR1 sequence as set forth in SEQ ID NO: 179, a CDR2 sequence as set forth in: DNN and a CDR3 sequence as set forth SEQ ID NO:180;
(k) a VH region comprising a CDR1 sequence as set forth in SEQ ID NO:182, a CDR2 sequence as set forth in SEQ ID NO:183 and a CDR3 sequence as set forth SEQ ID NO:184, and a VL region comprising a CDR1 sequence as set forth in SEQ ID NO: 186, a CDR2 sequence as set forth in SEQ ID NO:DTS and a CDR3 sequence as set forth SEQ ID NO:187; and
(l) a VH region comprising a CDR1 sequence as set forth in SEQ ID NO:189, a CDR2 sequence as set forth in SEQ ID NO:190 and a CDR3 sequence as set forth SEQ ID NO:191, and a VL region comprising a CDR1 sequence as set forth in SEQ ID NO: 193, a CDR2 sequence as set forth in: ATS and a CDR3 sequence as set forth SEQ ID NO:194, wherein the first antibody and second antibody are not the same antibody.
14. The method according to claim 1 , wherein the disease is selected from the group consisting of: cancer, autoimmune disease, inflammatory disease, and infectious disease.
15. The method according to claim 14 , wherein the method comprises administering an additional therapeutic agent.
16. A method of depleting a cell population expressing a first antigen and a second antigen, which method comprises contacting said cell population with a first antibody and second antibody, wherein the first antibody and second antibody are as defined in claim 1 .
17. A kit comprising a first container comprising a first antibody and a second container comprising a second antibody, wherein the first antibody and second antibody are as defined in claim 1 .